US72941H5090 - Common Stock
PLUS THERAPEUTICS INC
NASDAQ:PSTV (5/3/2024, 7:13:50 PM)
1.8
0 (0%)
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The company is headquartered in Austin, Texas and currently employs 17 full-time employees. The company went IPO on 2000-08-09. The firm is focused on developing treatments for patients battling cancer. The firm develops a targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. Its lead radiotherapeutic candidate, Rhenium (186Re) obisbemeda is designed specifically to CNS cancers including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. The Company’s portfolio also includes 188RNL-BAM, a radioembolization therapy for liver cancer.
PLUS THERAPEUTICS INC
4200 Marathon Blvd Ste 200
Austin TEXAS 78756
P: 17372557194
CEO: Marc. H. Hedrick
Employees: 17
Website: http://www.plustherapeutics.com/
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense...
The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic...
PSTV stock results show that Plus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Plus Therapeutics (NASDAQ:PSTV) just reported results for the fourth quarter of...
Began enrollment of the 5th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium (186Re) obisbemeda for...
Plus Therapeutics expects an additional $6.9 million in grant revenue in 2024, along with a lower interest rate and deferred principal payments on a debt...
Here you can normally see the latest stock twits on PSTV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: